Aspen Pharmacare Australia will manage the distribution and marketing of the product, should it receive the green light from local regulators. The application relies on data from two pivotal Phase 3 trials, NEAR-1 and NEAR-2, which tracked over 600 adults. Participants in these studies achieved a statistically significant 3-line gain in distance-corrected near visual acuity by the eighth day of use, with minimal reported side effects.

Elad Kedar, CEO of Orasis, described the filing as a major step in broadening global access to non-invasive alternatives for reading glasses. The treatment utilizes the EyeQ Formulation, designed to improve near vision through pupil modulation, creating a pinhole effect that increases depth of field. Aspen anticipates a potential launch in Australia next year, aiming to integrate the drops into its existing portfolio of over 150 medical brands.